secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001628280-22-013437
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed
------------------------------------------------------------------------

- Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.
- Maintains FY2022 LUPKYNIS revenue guidance $115-$135M, representing 150-200% growth over FY2021.
- Patients on LUPKYNIS reached ~1,071 at March 31, 2022, up 21% from 884 at December 31, 2021.
- EMA review on track; European Commission decision expected in second half of 2022.
- Cash, cash equivalents and investments $418.8M at March 31, 2022, down from $466.1M at year-end 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/0001628280-22-013437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/auph-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-013437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer